FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162289072> ?p ?o ?g. }

• W2162289072 endingPage "1331.e5" @default.
• W2162289072 startingPage "1324" @default.
• W2162289072 abstract "ObjectiveIncreased vascularization is considered an important contributing factor for plaque vulnerability. Microvascular proliferative disease in patients with diabetes results in renal damage and visual loss. We assessed the hypothesis that vascularization in carotid atherosclerotic tissue is increased in diabetic patients, especially in the critical shoulder regions of the plaque.MethodsCarotid endarterectomy specimens, clinical data, and blood samples were collected from patients with symptomatic carotid artery stenosis (median 85 days after clinical event) and pharmacologic treatment for diabetes (n = 26) or no diabetes (n = 85). Plaques were fixed in formalin and transverse tissue sections prepared. Histopathology and immunohistochemistry were performed for detection of endothelial cells (anti-CD34), macrophages (anti-CD68), vascular endothelial growth factor (VEGF), and its receptor (VEGFR-2). Neovascularization was assessed as CD34+ neovessel density in the entire section area and by the presence or absence of CD34+ vessels in the shoulder and cap regions of the plaques.ResultsThe patient groups did not differ significantly in neovascularization in the entire transverse sections (2.0 vs 2.1 vessels/mm2; P = .61) or in the fibrous cap (52% of the patients in both groups; P = .95). Neovascularization of the plaque shoulder regions was observed in 52% of the diabetic patients and in 26% of the nondiabetic patients (P = .028). VEGF-stained areas were similar in the two patient groups (0.4% and 0.2% of shoulder area; P = .61). Patients with diabetes had more VEGFR-2 (1.0% vs 0.2% of shoulder area; P < .016) and less CD68 staining (0.4% vs 3.6% of shoulder area; P < .008). Time from clinical event to surgery was positively associated with neovascularization of the plaque shoulder regions (≤90 days, 18% of patients; >90 days, 50% of patients; P = .002), independently of diabetes status.ConclusionsDiabetes was associated with increased vascularization of the shoulder regions in patients with symptomatic carotid atherosclerotic plaques. This was accompanied by increased expression of VEGFR-2. The increased vascularization of the plaque shoulder regions may help explain why patients with diabetes are at increased risk of atherosclerotic complications. Increased vascularization is considered an important contributing factor for plaque vulnerability. Microvascular proliferative disease in patients with diabetes results in renal damage and visual loss. We assessed the hypothesis that vascularization in carotid atherosclerotic tissue is increased in diabetic patients, especially in the critical shoulder regions of the plaque. Carotid endarterectomy specimens, clinical data, and blood samples were collected from patients with symptomatic carotid artery stenosis (median 85 days after clinical event) and pharmacologic treatment for diabetes (n = 26) or no diabetes (n = 85). Plaques were fixed in formalin and transverse tissue sections prepared. Histopathology and immunohistochemistry were performed for detection of endothelial cells (anti-CD34), macrophages (anti-CD68), vascular endothelial growth factor (VEGF), and its receptor (VEGFR-2). Neovascularization was assessed as CD34+ neovessel density in the entire section area and by the presence or absence of CD34+ vessels in the shoulder and cap regions of the plaques. The patient groups did not differ significantly in neovascularization in the entire transverse sections (2.0 vs 2.1 vessels/mm2; P = .61) or in the fibrous cap (52% of the patients in both groups; P = .95). Neovascularization of the plaque shoulder regions was observed in 52% of the diabetic patients and in 26% of the nondiabetic patients (P = .028). VEGF-stained areas were similar in the two patient groups (0.4% and 0.2% of shoulder area; P = .61). Patients with diabetes had more VEGFR-2 (1.0% vs 0.2% of shoulder area; P < .016) and less CD68 staining (0.4% vs 3.6% of shoulder area; P < .008). Time from clinical event to surgery was positively associated with neovascularization of the plaque shoulder regions (≤90 days, 18% of patients; >90 days, 50% of patients; P = .002), independently of diabetes status. Diabetes was associated with increased vascularization of the shoulder regions in patients with symptomatic carotid atherosclerotic plaques. This was accompanied by increased expression of VEGFR-2. The increased vascularization of the plaque shoulder regions may help explain why patients with diabetes are at increased risk of atherosclerotic complications." @default.
• W2162289072 created "2016-06-24" @default.
• W2162289072 creator A5010716333 @default.
• W2162289072 creator A5015326593 @default.
• W2162289072 creator A5029540440 @default.
• W2162289072 creator A5038799234 @default.
• W2162289072 creator A5060451270 @default.
• W2162289072 creator A5091430234 @default.
• W2162289072 date "2011-11-01" @default.
• W2162289072 modified "2023-10-03" @default.
• W2162289072 title "Increased vascularization of shoulder regions of carotid atherosclerotic plaques from patients with diabetes" @default.
• W2162289072 cites W1582116206 @default.
• W2162289072 cites W1966307362 @default.
• W2162289072 cites W1968903249 @default.
• W2162289072 cites W1998206832 @default.
• W2162289072 cites W1999504816 @default.
• W2162289072 cites W2002131026 @default.
• W2162289072 cites W2031820286 @default.
• W2162289072 cites W2033486658 @default.
• W2162289072 cites W2036397809 @default.
• W2162289072 cites W2060635550 @default.
• W2162289072 cites W2071740677 @default.
• W2162289072 cites W2075045160 @default.
• W2162289072 cites W2083222165 @default.
• W2162289072 cites W2084818589 @default.
• W2162289072 cites W2087175050 @default.
• W2162289072 cites W2091774189 @default.
• W2162289072 cites W2092692976 @default.
• W2162289072 cites W2096061445 @default.
• W2162289072 cites W2097631243 @default.
• W2162289072 cites W2102267931 @default.
• W2162289072 cites W2124008781 @default.
• W2162289072 cites W2124764915 @default.
• W2162289072 cites W2145478166 @default.
• W2162289072 cites W2147525200 @default.
• W2162289072 cites W2167755544 @default.
• W2162289072 cites W2170469020 @default.
• W2162289072 cites W2325727928 @default.
• W2162289072 cites W4211205882 @default.
• W2162289072 doi "https://doi.org/10.1016/j.jvs.2011.04.061" @default.
• W2162289072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21764240" @default.
• W2162289072 hasPublicationYear "2011" @default.
• W2162289072 type Work @default.
• W2162289072 sameAs 2162289072 @default.
• W2162289072 citedByCount "23" @default.
• W2162289072 countsByYear W21622890722013 @default.
• W2162289072 countsByYear W21622890722014 @default.
• W2162289072 countsByYear W21622890722015 @default.
• W2162289072 countsByYear W21622890722016 @default.
• W2162289072 countsByYear W21622890722017 @default.
• W2162289072 countsByYear W21622890722019 @default.
• W2162289072 countsByYear W21622890722020 @default.
• W2162289072 countsByYear W21622890722021 @default.
• W2162289072 countsByYear W21622890722022 @default.
• W2162289072 crossrefType "journal-article" @default.
• W2162289072 hasAuthorship W2162289072A5010716333 @default.
• W2162289072 hasAuthorship W2162289072A5015326593 @default.
• W2162289072 hasAuthorship W2162289072A5029540440 @default.
• W2162289072 hasAuthorship W2162289072A5038799234 @default.
• W2162289072 hasAuthorship W2162289072A5060451270 @default.
• W2162289072 hasAuthorship W2162289072A5091430234 @default.
• W2162289072 hasBestOaLocation W21622890721 @default.
• W2162289072 hasConcept C10205521 @default.
• W2162289072 hasConcept C126322002 @default.
• W2162289072 hasConcept C134018914 @default.
• W2162289072 hasConcept C142724271 @default.
• W2162289072 hasConcept C167734588 @default.
• W2162289072 hasConcept C204232928 @default.
• W2162289072 hasConcept C2776460901 @default.
• W2162289072 hasConcept C2777025900 @default.
• W2162289072 hasConcept C2778271429 @default.
• W2162289072 hasConcept C2779179121 @default.
• W2162289072 hasConcept C2779745121 @default.
• W2162289072 hasConcept C2780007028 @default.
• W2162289072 hasConcept C2780394083 @default.
• W2162289072 hasConcept C2781068581 @default.
• W2162289072 hasConcept C28328180 @default.
• W2162289072 hasConcept C54355233 @default.
• W2162289072 hasConcept C555293320 @default.
• W2162289072 hasConcept C71924100 @default.
• W2162289072 hasConcept C86803240 @default.
• W2162289072 hasConceptScore W2162289072C10205521 @default.
• W2162289072 hasConceptScore W2162289072C126322002 @default.
• W2162289072 hasConceptScore W2162289072C134018914 @default.
• W2162289072 hasConceptScore W2162289072C142724271 @default.
• W2162289072 hasConceptScore W2162289072C167734588 @default.
• W2162289072 hasConceptScore W2162289072C204232928 @default.
• W2162289072 hasConceptScore W2162289072C2776460901 @default.
• W2162289072 hasConceptScore W2162289072C2777025900 @default.
• W2162289072 hasConceptScore W2162289072C2778271429 @default.
• W2162289072 hasConceptScore W2162289072C2779179121 @default.
• W2162289072 hasConceptScore W2162289072C2779745121 @default.
• W2162289072 hasConceptScore W2162289072C2780007028 @default.
• W2162289072 hasConceptScore W2162289072C2780394083 @default.
• W2162289072 hasConceptScore W2162289072C2781068581 @default.
• W2162289072 hasConceptScore W2162289072C28328180 @default.
• W2162289072 hasConceptScore W2162289072C54355233 @default.
• W2162289072 hasConceptScore W2162289072C555293320 @default.

• next